Consun Pharmaceutical Group Limited (HKG:01681) saw its stock price soar by 5.04% during intraday trading on Tuesday, following the release of its impressive half-year financial results for 2025. The pharmaceutical company reported significant growth in both revenue and profit, surpassing market expectations.

According to the company's filing to the Hong Kong Stock Exchange, Consun Pharma's attributable profit for the first half of 2025 reached RMB498.3 million, marking a substantial 25% increase from RMB399.8 million in the same period last year. The company's revenue also saw a strong 24% year-on-year growth, rising to RMB1.57 billion. Earnings per share improved to 0.58 yuan, up from 0.49 yuan in the prior year.

Investors were particularly encouraged by Consun Pharma's robust gross margin of 77.1%, indicating the company's strong pricing power and operational efficiency. Furthermore, the board of directors declared an interim dividend of HKD0.33 per share, payable on September 19 to shareholders of record on September 5. This generous dividend payout likely contributed to the positive market reaction, as it signals management's confidence in the company's financial health and future prospects.